New twists in the AXL(e) of tumor progression

Balazs Halmos, Eric B. Haura

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Patients with a mesenchymal subtype of ovarian cancer face a poor prognosis with limited treatment options to halt metastatic progression. In this issue of Science Signaling, Antony et al. found that the kinase AXL drives the mesenchymal gene signature and motility of ovarian tumor cells. AXL inhibitors may thus slow tumor progression in this subset of patients. 2016

Original languageEnglish (US)
Article numberfs14
JournalScience Signaling
Volume9
Issue number448
DOIs
StatePublished - Oct 4 2016

Fingerprint

Tumors
Ovarian Neoplasms
Neoplasms
Phosphotransferases
Genes
Cells
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

New twists in the AXL(e) of tumor progression. / Halmos, Balazs; Haura, Eric B.

In: Science Signaling, Vol. 9, No. 448, fs14, 04.10.2016.

Research output: Contribution to journalArticle

Halmos, Balazs ; Haura, Eric B. / New twists in the AXL(e) of tumor progression. In: Science Signaling. 2016 ; Vol. 9, No. 448.
@article{cdb7610119e844c59967424e1118dc94,
title = "New twists in the AXL(e) of tumor progression",
abstract = "Patients with a mesenchymal subtype of ovarian cancer face a poor prognosis with limited treatment options to halt metastatic progression. In this issue of Science Signaling, Antony et al. found that the kinase AXL drives the mesenchymal gene signature and motility of ovarian tumor cells. AXL inhibitors may thus slow tumor progression in this subset of patients. 2016",
author = "Balazs Halmos and Haura, {Eric B.}",
year = "2016",
month = "10",
day = "4",
doi = "10.1126/scisignal.aai7619",
language = "English (US)",
volume = "9",
journal = "Science Signaling",
issn = "1937-9145",
publisher = "American Association for the Advancement of Science",
number = "448",

}

TY - JOUR

T1 - New twists in the AXL(e) of tumor progression

AU - Halmos, Balazs

AU - Haura, Eric B.

PY - 2016/10/4

Y1 - 2016/10/4

N2 - Patients with a mesenchymal subtype of ovarian cancer face a poor prognosis with limited treatment options to halt metastatic progression. In this issue of Science Signaling, Antony et al. found that the kinase AXL drives the mesenchymal gene signature and motility of ovarian tumor cells. AXL inhibitors may thus slow tumor progression in this subset of patients. 2016

AB - Patients with a mesenchymal subtype of ovarian cancer face a poor prognosis with limited treatment options to halt metastatic progression. In this issue of Science Signaling, Antony et al. found that the kinase AXL drives the mesenchymal gene signature and motility of ovarian tumor cells. AXL inhibitors may thus slow tumor progression in this subset of patients. 2016

UR - http://www.scopus.com/inward/record.url?scp=84990210511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990210511&partnerID=8YFLogxK

U2 - 10.1126/scisignal.aai7619

DO - 10.1126/scisignal.aai7619

M3 - Article

C2 - 27703029

AN - SCOPUS:84990210511

VL - 9

JO - Science Signaling

JF - Science Signaling

SN - 1937-9145

IS - 448

M1 - fs14

ER -